Senores Pharmaceuticals through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt.
Enalapril is indicated as a treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. The market size of Enalapril Tablet in the USA was around $28.60 million (MAT December 2024) as per IQVIA and around $109.24 million (MAT March 2025) as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by Senores Pharmaceuticals. This is in line with the objects of the IPO stated in the Red Herring Prospectus.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
